CGRP receptor antagonists (gepants).
Handb Clin Neurol
; 199: 51-66, 2024.
Article
em En
| MEDLINE
| ID: mdl-38307667
ABSTRACT
Small molecule calcitonin gene-related peptide (CGRP) receptor antagonists are commonly referred to as gepants. The first generation of gepants provided the first line of evidence of CGRP-mediated antimigraine medication in 2004-2011. However, further development was halted due to either lack of oral availability or concerns of hepatotoxicity. More than 15 years later, the first second generation of gepants, ubrogepant and rimegepant, are now approved for the acute treatment of migraine with or without aura. Furthermore, a novel and promising third-generation gepant, zavegepant, has recently been approved as well. In this chapter, we review the evidence supporting the effectiveness, safety, and tolerability of gepants for the acute treatment of migraine. Furthermore, we discuss the potential limitations and future directions of this class of migraine-specific medication.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina
/
Transtornos de Enxaqueca
Limite:
Humans
Idioma:
En
Revista:
Handb Clin Neurol
Ano de publicação:
2024
Tipo de documento:
Article